A controlled trial of recombinant human erythropoietin after bone marrow transplantation

Hartmut Link, Marc A. Boogaerts, Axel A. Fauser, Shimon Slavin, Josy Reiffers, Norbert C. Gorin, Angelo M. Carella, Franco Mandelli, Stephan Burdach, Augustin Ferrant, Werner Linkesch, Sante Tura, Andrea Bacigalupo, Fritz Schindel, Hubert Heinrichs

Research output: Contribution to journalArticlepeer-review

86 Scopus citations


Recombinant human erythropoietin (rHuEPO) stimulates erythropoietic bone marrow cells and increases erythrocyte production. This prospective study was designed to evaluate the effects of rHuEPO on regeneration of erythropoiesis after allogeneic or autologous bone marrow transplantation (BMT). Seventeen centers participated in this randomized, double-blind, placebo-controlled multicenter trial. The randomization was performed centrally for each center and stratified according to allogeneic or autologous BMT and major ABO-blood group incompatibility. One hundred and six patients received rHuEPO after allogeneic BMT and 109 patients received placebo. After autologous BMT, 57 patients were treated with rHuEPO and 57 with placebo. Patients received either 150 IU/kg/day C127 mouse-cell-derived rHuEPO or placebo as continuous intravenous infusion. Therapy started after bone marrow infusion and lasted until independence from erythrocyte transfusions for 7 consecutive days with stable hemoglobin levels ≥9 g/100 mL or until day 41. After allogeneic BMT, the reticulocyte counts were significantly higher with rHuEPO from day 21 to day 42 after BMT. The median time (95% confidence intervals) to erythrocyte transfusion independence was 19 days (range, 16.3 to 21.6) with rHuEPO and 27 days (range, 22.3 to >42) with placebo (P < .003). The mean (±SD) numbers of erythrocyte transfusions until day 20 after BMT were 6.6 ± 4.8 with rHuEPO and 6.0 ± 3.8 with placebo. However, from day 21 to day 41, the rHuEPO- treated patients received 1.4 ± 2.5 (median, 0) transfusions and the control group received 2.7 ± 4.0 (median, 2) transfusions (P = .004). In the follow- up period from day 42 up to day 100, 2.4 ± 5.6 transfusions were required with rHuEPO and 4.5 ± 9.6 were required with placebo (P = .075). A multivariate analysis (ANOVA) showed that acute graft-versus-host disease (GVHD), major ABO-blood group incompatibility, age greater than 35 years, and hemorrhage significantly increased the number of transfusions. However, after day 20, rHuEPO significantly reduced the number of erythrocyte transfusions in these patient groups, as well as reducing incompatibility in the major ABO-blood group. For the whole study period, rHuEPO reduced the transfusion requirements in GVHD III and IV from 18.4 ± 8.6 to 8.5 ± 6.8 U (P = .05). After autologous BMT, there was no difference in the time to independence from erythrocyte transfusions and in the regeneration of reticulocytes. Marrow purging strongly increased the requirement for transfusions as well as the time to transfusion independence. rHuEPO had no relevant effect on regeneration of thrombopoiesis after allogeneic or autologous BMT. Overall, no major differences in side effects or complications between rHuEPO-treated and placebo-treated patients occurred. After allogeneic BMT, rHuEPO significantly accelerates the reconstitution of erythropoiesis and reduces the number of erythrocyte transfusions after day 20. The strongest effect occurs in patients with acute GVHD. After autologous BMT, rHuEPO has no clinically relevant effect on regeneration of erythropoiesis.

Original languageEnglish
Pages (from-to)3327-3335
Number of pages9
Issue number10
StatePublished - 15 Nov 1994


Dive into the research topics of 'A controlled trial of recombinant human erythropoietin after bone marrow transplantation'. Together they form a unique fingerprint.

Cite this